187 related articles for article (PubMed ID: 32017375)
1. Sézary syndrome and mycosis fungoides flow cytometric evaluation: The clinicians' perspective.
Guitart J
Cytometry B Clin Cytom; 2021 Mar; 100(2):129-131. PubMed ID: 32017375
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
[TBL] [Abstract][Full Text] [Related]
3. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.
Pulitzer MP; Horna P; Almeida J
Cytometry B Clin Cytom; 2021 Mar; 100(2):132-138. PubMed ID: 32516521
[TBL] [Abstract][Full Text] [Related]
4. It is time to adopt a multicolor immunophenotyping approach to evaluate blood for Sézary syndrome and mycosis fungoides.
Craig FE
Cytometry B Clin Cytom; 2021 Mar; 100(2):125-128. PubMed ID: 32083391
[No Abstract] [Full Text] [Related]
5. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics.
Horna P; Wang SA; Wolniak KL; Psarra K; Almeida J; Illingworth AJ; Johansson U; Craig FE; Torres R
Cytometry B Clin Cytom; 2021 Mar; 100(2):142-155. PubMed ID: 32319723
[TBL] [Abstract][Full Text] [Related]
6. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK; Mullins FM; Kim YH; Kong CS
Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
[TBL] [Abstract][Full Text] [Related]
7. International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors.
Illingworth A; Johansson U; Huang S; Horna P; Wang SA; Almeida J; Wolniak KL; Psarra K; Torres R; Craig FE
Cytometry B Clin Cytom; 2021 Mar; 100(2):156-182. PubMed ID: 33112044
[TBL] [Abstract][Full Text] [Related]
8. Follicular center helper T-cell (TFH) marker positive mycosis fungoides/Sezary syndrome.
Meyerson HJ; Awadallah A; Pavlidakey P; Cooper K; Honda K; Miedler J
Mod Pathol; 2013 Jan; 26(1):32-43. PubMed ID: 22918164
[TBL] [Abstract][Full Text] [Related]
9. Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy.
Klein RS; Dunlop JD; Samimi SS; Morrissey KA; Evans KG; Gardner JM; Introcaso CE; Vittorio CC; Rook AH; Micaily B; Kim EJ
J Am Acad Dermatol; 2013 Jun; 68(6):972-7. PubMed ID: 23415461
[TBL] [Abstract][Full Text] [Related]
10. Screening tests for Sezary cells in cutaneous T-cell lymphomas.
Newton JA; Guthrie DL; Westwood NB; Pearson TC; Camplejohn RS; Smith N
Clin Lab Haematol; 1986; 8(2):109-14. PubMed ID: 3488168
[TBL] [Abstract][Full Text] [Related]
11. Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome.
Wada DA; Wilcox RA; Harrington SM; Kwon ED; Ansell SM; Comfere NI
Am J Hematol; 2011 Mar; 86(3):325-7. PubMed ID: 21328438
[No Abstract] [Full Text] [Related]
12. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
[TBL] [Abstract][Full Text] [Related]
13. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.
Yamashita T; Abbade LP; Marques ME; Marques SA
An Bras Dermatol; 2012; 87(6):817-28; quiz 829-30. PubMed ID: 23197199
[TBL] [Abstract][Full Text] [Related]
14. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
[TBL] [Abstract][Full Text] [Related]
15. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--Part I.
Safai B
Clin Bull; 1977; 7(3):91-7. PubMed ID: 308870
[No Abstract] [Full Text] [Related]
17. Ultrastructural morphometry in the diagnosis of mycosis fungoides and Sézary's syndrome.
Payne CM
Clin Dermatol; 1991; 9(2):187-203. PubMed ID: 1747854
[No Abstract] [Full Text] [Related]
18. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
19. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
Hoppe RT; Wood GS; Abel EA
Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
